Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2015

View Archived Issues

LECIGon achieves primary endpoint in pivotal E.U. study

Ipsen and OncoDesign disclose LRRK2 inhibitor ODS-2005294

TetraLogic receives FDA clearance to start phase II trial of SHAPE in alopecia areata

TiGenix receives E.U. grant to support trial of Cx-611 in severe sepsis

Antimalarial AQ-13 receives U.S. orphan drug designation

Mitsubishi Tanabe Pharma reviews highlights of second quarter of fiscal 2015

AbbVie describes GlyT1 inhibitor schizophrenia candidate ABT-419

Porcine models used to evaluate stent strategies

Shionogi reviews progress of second quarter of fiscal 2015

Cellectar Biosciences advances PDC chemotherapeutic program

Ironwood Pharmaceuticals begins studies of IW-1973 and IW-1701

Regulus expands development of RG-101

Janssen R&D Ireland reports anti-RSV agents

Jiangsu Hengrui Medicine patents mPGES-1 inhibitors

Gruenenthal introduces Cav2.2 channel blockers

Emory University and Cocrystal Pharma introduce HCV NS5A inhibitors

Shanghai De Novo Pharmatech divulges SGLT2 inhibitors

Novo Nordisk advances pipeline in third quarter 2015

FDA grants priority review to Acadia's NDA for Nuplazid for PD-associated psychosis

Launch of managed access program for Unituxin

CP-628006, novel CFTR potentiator has additive effects with ivacaftor on G551D CFTR function

Sodium and chloride in saliva might be useful biomarkers for CF diagnosis

Sun Pharma completes acquisition of InSite Vision

Boehringer Ingelheim initiates pivotal program for BI-1482694 in NSCLC

MicuRx reports results from second phase II trial of MRX-I in ABSSSI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...